Off-label uses of drugs for depression

被引:33
|
作者
Skanland, Sigrid S. [1 ,2 ,3 ]
Cieslar-Pobuda, Artur [1 ,3 ,4 ]
机构
[1] Oslo Univ Hosp, Inst Canc Res, Dept Canc Immunol, Oslo, Norway
[2] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Inst Clin Med, Oslo, Norway
[3] Univ Oslo, KG Jebsen Ctr Canc Immunotherapy, Inst Clin Med, Oslo, Norway
[4] Univ Oslo, Ctr Mol Med Norway NCMM, Nordic EMBL Partnership, Oslo, Norway
关键词
Antidepressants; Chronic pain; Eating disorders; Off-label; Sleep disorders; Smoking cessation; MENOPAUSAL VASOMOTOR SYMPTOMS; PERIPHERAL NEUROPATHIC PAIN; SUSTAINED-RELEASE BUPROPION; HOT FLASHES; PHARMACOLOGICAL-TREATMENT; ANOREXIA-NERVOSA; PREMATURE EJACULATION; PSYCHIATRIC-DISORDERS; MIGRAINE PROPHYLAXIS; NICOTINE WITHDRAWAL;
D O I
10.1016/j.ejphar.2019.172732
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The prescription of drugs for depression is rising rapidly. One of the reasons for this trend is their many off-label uses. Up to one third of all prescriptions are for non-indicated use, which in addition to drug repurposing includes different dosing or duration than those recommended. In this review, we elaborate on what antidepressants can treat besides depression. The five classes of drugs for depression are introduced, and their mechanisms of action and serious side effects are described. The most common off-label uses of antidepressants are discussed, with a special focus on treating eating disorders, sleep problems, smoking cessation and managing chronic pain. Depression is often a comorbidity when antidepressants are chosen as therapy, but good therapeutic effects have been observed for other conditions also when depression is not involved. Finally, a new type of antidepressant developed from the hallucinogenic "party drug" ketamine is briefly introduced. This recent development suggests that antidepressants will keep playing a central role in medicine for years to come.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Ivabradine: A Review of Labeled and Off-Label Uses
    Carrie S. Oliphant
    Ryan E. Owens
    Oluwaseyi B. Bolorunduro
    Sunil K. Jha
    [J]. American Journal of Cardiovascular Drugs, 2016, 16 : 337 - 347
  • [32] New and Off-Label Uses of Tranexamic Acid
    Johnson, Stephanie M.
    Tsang, Dawn
    Dansby, Mary
    Allen, Christopher
    [J]. AACN ADVANCED CRITICAL CARE, 2021, 32 (03) : 237 - 242
  • [33] Polidocanol: A Review of Off-Label Dermatologic Uses
    Nguyen, Quoc-Bao D.
    Stender, Carly
    Bur, Delfina
    Silapunt, Sirunya
    [J]. DERMATOLOGIC SURGERY, 2022, 48 (09) : 961 - 966
  • [34] Off-label use of approved drugs
    Landow, L
    [J]. CHEST, 1999, 116 (03) : 589 - 591
  • [35] Off-label drugs for obesity Comment
    Proietto, Joseph
    [J]. AUSTRALIAN PRESCRIBER, 2022, 45 (04) : 114 - 114
  • [36] Off-label subcutaneous administration of drugs
    Pardo-Pastor, J.
    Modamio, P.
    Pardo, C.
    Lastra, C. F.
    Mas, P.
    Marino, E. L.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 966 - 967
  • [37] Controlled use of off-label drugs
    Seeber, S
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (09) : 1189 - 1189
  • [38] Off-label and unlicensed drugs in neonatology
    Rite-Gracia, Segundo
    Avila-Alvarez, Alejandro
    [J]. ANALES DE PEDIATRIA, 2021, 94 (03): : 127 - 128
  • [39] Guidance for off-label use of drugs
    不详
    [J]. LANCET NEUROLOGY, 2008, 7 (04): : 285 - 285
  • [40] Off-Label Use of Drugs in Children
    Frattarelli, Daniel A. C.
    Galinkin, Jeffrey L.
    Green, Thomas P.
    Johnson, Timothy D.
    Neville, Kathleen A.
    Paul, Ian M.
    Van den Anker, John N.
    Knight, Matthew
    Alexander, John J.
    Kilpatrick, Sarah J.
    Cragan, Janet D.
    Rieder, Michael J.
    Robb, Adelaide S.
    Sachs, Hari
    Zajicek, Anne
    Haro, Tamar
    Koteras, Raymond K.
    Del Monte, Mark
    [J]. PEDIATRICS, 2014, 133 (03) : 563 - 567